Navigation Links
ULURU Inc. Reports Third Quarter 2013 Financial Results
Date:11/15/2013

ADDISON, Texas, Nov. 15, 2013 /PRNewswire/ -- ULURU Inc. (OTCQB: ULUR) today announced its financial results for the third quarter ended September 30, 2013 and provided a review of its operating activities.

During the third quarter, continued progress was made towards the expansion of commercialization of Altrazeal® in international markets:

  • Orders of Altrazeal® were shipped to five new markets in September and October 2013; the Czech Republic, Slovakia, South Africa, Croatia and Slovenia;
  • Production of Altrazeal® has been initiated in the fourth quarter 2013 for eight additional markets;
  • In September 2013, we executed a License and Supply Agreement with Altrazeal AG to market Altrazeal® in several new territories, to include Africa (markets not already licensed), Latin America, the Commonwealth of Independent States, Georgia, Ukraine, and Turkmenistan. Under the terms of the agreement with Altrazeal AG, we received an up-front licensing payment, will receive certain royalties on product sales within the territories, and will supply Altrazeal® at an agreed upon price; and
  • Since the beginning of the third quarter 2013, we announced the further expansion of the Altrazeal® international marketing network to include 16 additional countries including, Scandinavia, Finland, South Africa, Czech Republic, Slovakia, Portugal, Croatia, and Slovenia.
  • Other noteworthy events include the Company's capital structure being simplified through the redemption of all outstanding shares of preferred stock. In addition, the results of our randomized study were published in the peer reviewed International Wound Journal.

    Commenting on the business activities, Kerry P. Gray, President and CEO, stated, "Outstanding progress has been made on numerous fronts during the past quarter. We believe we are significantly ahead of schedule in achieving our objective of having Altrazeal® launched in 50 markets by the end of 2014. The breadth and extent of interest shown by potential strategic marketing partners gives us great confidence that our commercialization objectives will be achieved."

    For the third quarter of 2013, the Company reported a net loss of $0.7 million, or $0.05 per share, compared with a net loss of $0.9 million, or $0.10 per share, for the same period last year. For the nine months ended September 30, 2013, the reported net loss was $2.2 million, or $0.16 per share, compared with a net loss of $2.6 million, or $0.32 per share, for the same period last year.

    Commenting on the financial results Kerry P. Gray, President and CEO, stated, "Despite a significant increase in commercial activities, principally production and the associated quality compliance issues associated with growth in Altrazeal® product sales, we have continued to reduce our operating expenses during 2013 as our operating expenses are $464,000 below prior year. This has been the principal reason for a reduction in the reported loss. With the reduced expense base we are well positioned to more rapidly achieve profitability with the anticipated revenue expansion in the next six months."

    Operating ResultsRevenues
    Revenues were $111,000 for the third quarter of 2013, as compared to $89,000 for the third quarter of 2012. The increase of approximately $22,000 in revenues is primarily attributable to an increase in Altrazeal® product sales and royalties, partially offset by a decrease of $16,000 in royalties related to the domestic sale of Aphthasol®.

    Revenues were $242,000 for the nine months ended September 30, 2013, as compared to $205,000 for the comparative period of 2012. The increase of approximately $37,000 in revenues is primarily attributable to an increase of Altrazeal® product sales, royalties and licensing fees which were partially offset by a decrease of $50,000 in royalties related to the domestic sale of Aphthasol®, as a result of the patent expiration and resulting license termination.

    Research and Development
    Research and development expenses were $201,000 for the third quarter of 2013, including $5,000 in share-based compensation, as compared to $153,000 for the third quarter 2012, which included no share-based compensation. The increase of approximately $48,000 in research and development expenses was entirely due to an increase of $54,000 in personnel expense.

    Research and development expenses were $578,000 for the nine months ended September 30, 2013, including $12,000 in share-based compensation, as compared to $517,000 for the nine months ended September 30, 2012, which included $9,000 in share-based compensation. The increase of approximately $61,000 in research and development expenses was primarily due to an increase of $85,000 in personnel expense which was partially offset by a decrease of $20,000 in clinical study costs.

    Selling, General and Administrative
    Selling, general and administrative expenses were $302,000 for the third quarter of 2013, including $20,000 in share-based compensation, as compared to $376,000 for the third quarter of 2012, which included $8,000 in share-based compensation. The decrease of approximately $74,000 in selling, general and administrative expenses was primarily due to a decrease of $109,000 in sales & marketing costs due to a revised sales and marketing plan and a lower head count, and a decrease of $20,000 related to accruals for bad debt expense. These expense decreases were partially offset by an increase of $35,000 in investor relations consulting and an increase of $11,000 in director fees.

    Selling, general and administrative expenses were $915,000 for the nine months ended September 30, 2013, including $45,000 in share-based compensation, as compared to $1,366,000 for the nine months ended September 30, 2012, which included $29,000 in share-based compensation. The decrease of approximately $451,000 in selling, general and administrative expenses was primarily due to a decrease of $323,000 in sales & marketing costs due to a revised sales and marketing plan and a lower head count, a decrease of $58,000 in investor relations consulting, a decrease of $43,000 in insurance costs and a decrease of $28,000 in bad debt expenses. These expense decreases were partially offset by an increase of $21,000 for director fees and an increase of $17,000 in legal fees.

    Interest and Miscellaneous Income
    Interest and miscellaneous income was $15,000 for the third quarter of 2013 as compared to $31,000 for the third quarter of 2012. The decrease of approximately $16,000 is attributable to a decrease in interest income resulting from a decrease in the outstanding notes receivable.

    Interest and miscellaneous income was $56,000 for the nine months ended September 30, 2013 as compared to $34,000 for the nine months ended September 30, 2012. The increase of approximately $22,000 is attributable to an increase in interest income resulting from interest recognized from the outstanding notes receivable.

    Interest Expense
    Interest expense was $126,000 for the third quarter of 2013 as compared to $134,000 for the third quarter of 2012.

    Interest expense was $386,000 for the nine months ended September 30, 2013 as compared to $191,000 for the nine months ended September 30, 2012. The increase of approximately $195,000 is primarily attributable to costs associated with our convertible debt.

    About ULURU Inc.:
    ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com. For further information about Altrazeal®, please visit our website at www.altrazeal.com.

    This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to future financial performance of ULURU Inc. (the "Company"), the expansion of commercialization of Altrazeal® in international markets, the anticipated timing for the launch of Altrazeal® in various markets and countries, the usage of Altrazeal® in 50 markets by the end of 2014, the anticipated escalation of revenues, positive cash flows, and improved profitability in 2013 and 2014, and the achievement of the Company's commercialization objectives.  When used in this press release, the words "believe," "expect" and "anticipate" and similar expressions may be indicative of forward-looking statements including without limitation statements relating to the regulatory results for our products.  These statements by their nature involve substantial risks and uncertainties, certain of which are beyond the Company's control. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of an unanticipated event. Further, management cannot assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2012 and other reports filed by us with the Securities and Exchange Commission.

    Contact: Company
    Kerry P. Gray
    President & CEO
    Terry K. Wallberg
    Vice President & CFO
    (214) 905-5145 ULURU Inc.SUMMARY OF RESULTSSTATEMENTS OF OPERATIONS DATAThree Months Ended September 30,Nine Months Ended September 30,2013201220132012RevenuesLicense fees

    $
    ,400$
    ,400$
    33,827$
    29,163Royalty income

    10,27616,63310,27649,918Product sales, net

    88,90460,889197,405126,057Total Revenues

    110,58088,922241,508205,138Costs and ExpensesCost of goods sold

    60,245113,415104,236135,745Research and development

    201,244152,985577,712517,196Selling, general and administrative

    302,093375,767914,5091,365,836Amortization of intangible assets

    119,763119,763355,385356,687Depreciation

    59,68875,219185,536225,691Total Costs and Expenses

    743,033837,1492,137,3782,601,155Operating (Loss)(632,453)(748,227)(1,895,870)(2,396,017)Other Income (Expense)Interest and miscellaneous income

    15,08830,72055,56433,745Interest expense

    (125,904)(134,218)(385,965)(191,008)Equity in earnings (loss) of unconsolidated subsidiary

    ------------Gain on sale of equipment

    ------3,627---(Loss) Before Income Taxes(743,269)(851,725)(2,222,644)(2,553,280)Income taxes

    ------------Net (Loss)$(743,269)$(851,725)$(2,222,644)$(2,553,280)Less preferred stock dividends

    (6,061)(12,288)(30,236)(35,168)Net (Loss) Allocable to Common Stockholders$(749,330)$(864,013)$(2,252,880)$(2,588,448)Basic and diluted net (loss) per common share

    $   (0.05)$   (0.10)$  (0.16)$  (0.32)Weighted average number of common shares outstanding

    15,659,8228,267,75513,677,1868,106,117 ULURU Inc. SELECTED CONDENSED CONSOLIDATED BALANCE SHEET DATASeptember 30, 2013December 31, 2012(Unaudited)(Audited)  Cash and cash equivalents

    $
    53,001$
    21,549  Current assets

    1,376,4511,115,982  Property and equipment, net

    690,718845,535  Other assets

    4,189,2095,366,600  Total assets

    6,256,3787,328,117  Current liabilities

    3,421,0953,889,734  Long term liabilities – convertible notes payable

    45,688751,543  Long term liabilities – deferred revenue

    912,994835,553  Total liabilities

    4,379,7775,476,830  Total stockholders' equity

    1,876,6011,851,287


    '/>"/>
    SOURCE ULURU Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. ULURU Inc. Announces Conference Call To Discuss Financial Results For The Third Quarter Ended September 30, 2013
    2. ULURU Inc. Completes Redemption Of Preferred Stock
    3. ULURU Inc. Reports Second Quarter 2013 Financial Results
    4. ULURU Inc. Announces Conference Call To Discuss Financial Results For The Second Quarter Ended June 30, 2013
    5. ULURU Inc. Reports First Quarter 2013 Financial Results
    6. ULURU Inc. Announces Conference Call To Discuss Financial Results For The First Quarter Ended March 31, 2013
    7. ULURU Inc. Reports Financial Results For Fourth Quarter And Year Ending December 31, 2012
    8. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2012 and to Provide a Business Update
    9. ULURU Inc. Business Update And Outlook
    10. ULURU Inc. Announces Closing Of $440,000 Private Placement
    11. ULURU Inc. Reports Third Quarter 2012 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/4/2016)... Medical, Inc. (Nasdaq: AEMD ), the pioneer ... diseases, today announced results for the third quarter ... --> --> "Beyond ... quarterly call, we strategically advanced pre-clinical and clinical ... the Aethlon Hemopurifier® as a leading broad-spectrum countermeasure ...
    (Date:2/4/2016)... N.Y. , Feb. 4, 2016  AMRI (NASDAQ:  AMRI) ... President of Pfizer Inc. and President of Pfizer Global Supply, ... as of February 4, 2016. In addition, the Company announced ... of the audit committee since 2010, has retired from the ... and attention to his other business ventures.  ...
    (Date:2/4/2016)... PUNE, India , February 4, 2016 ... to the new Market Research Report "North American Automated ... and Fully-Automated External Defibrillators), by End-User (Public Facilities, Hospitals, ... North American automated external defibrillators (AED) report defines and ... of the revenue. This market is estimated to grow ...
    Breaking Medicine Technology:
    (Date:2/6/2016)... ... February 06, 2016 , ... ... MEDIA ADVISORY: 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO ... in the world with an estimated 5000 perioperative nurses in attendance to ...
    (Date:2/5/2016)... ... February 05, 2016 , ... Steven Tonkinson, 36, of ... completed every year since it started in 2003. This year, he ran all 26.2 ... fellow runners and NBA team the Miami Heat. , This Sunday, while many are ...
    (Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
    (Date:2/5/2016)... ... February 05, 2016 , ... After years as an active staff surgeon ... and cosmetic surgeon Dr. Wayne Carman transitioned to chief of the Division of Plastic ... first three-year term as chief and began a second three-year term in January of ...
    (Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... gym use and find themselves having to wait longer to access the treadmills. It’s ... their New Year’s resolutions to lose weight and get in shape by joining gyms, ...
    Breaking Medicine News(10 mins):